Figures on vaccination
- 126 million doses delivered in the EU
- 100 million doses administered in the EU
Last update: 14 April 2021. Source: Vaccine producers and the ECDC data
Accelerating the delivery of vaccines
On 14 April, the European Commission reached an agreement with BioNTech-Pfizer to speed up the delivery of vaccines. 50 million additional doses, initially foreseen for the fourth quarter of 2021, will be delivered in the second quarter, starting in April. To prepare for the future, the Commission also announced it was entering into a negotiation with BioNTech-Pfizer for a third contract that would foresee the delivery of 1.8 billion doses of vaccine over the period of 2021 to 2023.
Information about vaccination in the EU
Securing doses of future vaccines
The European Commission has been negotiating intensely to build a diversified portfolio of vaccines for EU citizens at fair prices. Contracts have been concluded with 6 promising vaccine developers, securing a portfolio of more than 2.6 billion doses.
Deliveries of vaccine doses to European Union countries have increased steadily since December. Vaccination gathers pace across the European Union.
The Commission has so far given 4 conditional marketing authorisations for the vaccines developed by BioNTech and Pfizer, Moderna, AstraZeneca and Janssen Pharmaceutica NV following EMA positive assessment of their safety and efficacy. Several other vaccines are at different stages of assessment by the European Medicines Agency (EMA).
The Commission is working closely with the industry to step up vaccine manufacturing capacity in the EU.
At the same time, the Commission has started work to anticipate and tackle new variants of the virus and to rapidly develop and produce on a large-scale vaccines effective against those variants.
This is why the European Commission has launched the HERA Incubator. It will bring together science, industry and public authorities, to speed up work and leverage all available resources to enable Europe to respond to this threat.
- 2.6 billion doses
Type of vaccine
Number of doses
(needed per person)
Number of doses
|BioNTech and Pfizer||mRNA||2 doses||600 million||Approved|
|Moderna||mRNA||2 doses||460 million||Approved|
|CureVac||mRNA||2 doses||405 million||Development ongoing|
|AstraZeneca||adenovirus||2 doses||400 million||Approved|
|Johnson & Johnson/Janssen Pharmaceuticals||adenovirus||1 dose||400 million||Approved|
|Sanofi-GSK||protein||2 doses||300 million||Development ongoing|
The Commission has also concluded exploratory talks with
- Novavax with a view to purchasing up to 200 million doses, and
- Valneva with a view to purchase up to 60 million doses.
The European Medicines Agency publishes safety updates for the COVID-19 vaccines authorised in the EU. EMA releases a monthly update for each authorised COVID-19 vaccine.
The safety updates summarise the data that have become available since the vaccine's authorisation. They also indicate whether any safety information requires further investigation.
For more information, visit the EMA webpage.
Check the facts
Disinformation on the coronavirus is thriving. It is important that you get updated information from authoritative sources only. We suggest that you follow the advice of your public health authorities, and the websites of relevant EU and international organisations: the European Centre for Disease Control (ECDC ) and the World Health Organisation (WHO).
You can also help by not sharing unverified information that comes from dubious sources.
The EU vaccine strategy
With the EU Vaccine Strategy, the EU is supporting efforts to accelerate the development and availability of safe and effective vaccines in a timeframe between 12 and 18 months, if not earlier. Delivering on this complex task requires running clinical trials in parallel with investing in production capacity to be able to produce millions, or even billions, of doses of a successful vaccine.
Hear from the experts
Peter Piot, virologist
Dr Frank Ulrich Montgomery,
Hear from the people
Borislava Ananieva, transplant patient
Upcoming Global Health Summit
Italy, holding the Presidency of the G20, and the European Commission will co-host a Global Health Summit in Rome on 21 May 2021.
G20 Leaders, heads of international and regional organisations, and representatives of global health bodies will share lessons learned from the pandemic and agree on principles supporting further cooperation and joint action in preventing future global health crises, irrespective of origin.